2 not yet recruiting, 2 recruiting. 4 Phase 2, 3 Phase 1.
By phase and status
Follow GFH276: new trials by email Literature Review of GFH276 trials Research Report on GFH276
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
GFH276, with or without Tislelizumab, Pemetrexed - RAS Mutation, Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 84 | 2026-11-01 | 2026-09-29 |
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
GFH375, GFH276, GFS202A - Pancreatic Cancer | Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 120 | 2026-08-20 | 2026-10-02 |
A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
GFH276 - Cancer, PDAC | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 450 | 2025-09-22 | 2025-09-30 |
Conditions studied
Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
Sponsors
Genfleet Therapeutics (Shanghai) Inc. (4)
Countries
China (3) · Australia (1)
Top investigators
Ziming Li, MD (1)